CD24 and breast cancer: The discrepancy in the results of CD44hi/CD24lo previously reported in breast cancer was possibly due to differences in the (1) scoring method, (2) the CD24 antibody used especially clone SN3b, which is not very specific [28], (3) the intensity of CD44 or CD24 that was considered positive, and (4) whether the cohort of breast cancer patients used have received neoadjuvant chemotherapy therapy or not.